For IR Inquiries:
Harmony Biosciences is a private pharmaceutical company headquartered in Plymouth Meeting, PA. The company was established in October 2017, with a vision to develop and provide new medications to help people who are living with rare, neurological diseases.
In October 2017, the company acquired exclusive U.S. rights to develop, register and market the drug pitolisant from French company, Bioprojet SCR (Bioprojet) to address unmet needs for patients with sleep and other central nervous system disorders. Harmony’s financing has come from highly experienced equity investors including: Bioprojet; Fidelity Management and Research Company; HBM Healthcare Investments; Nan Fung LIfe Sciences; Novo Holdings; Paragon Biosciences, LLC; Valor Equity Partners; venBio Partners; Vivo Capital; Aisling Capital and Soros Fund Management.
Deal of the Year Award 2017
Harmony received Life Sciences Pennsylvania’s 2017 Deal of the Year award for the largest private equity investment in the biotech industry in Pennsylvania to acquire the exclusive U.S. rights to develop, register and market pitolisant from French company Bioprojet SCR.